Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivastigmine transdermal patch - Luye Pharma

Drug Profile

Rivastigmine transdermal patch - Luye Pharma

Alternative Names: Kingsmin; LY 03013; LY 30410; RID-TDS; Rivastigmine MD; Rivastigmine transdermal - Luye Pharma; Rivirec

Latest Information Update: 15 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acino
  • Developer Luye Pharma Group
  • Class Antidementias; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease

Most Recent Events

  • 05 Feb 2024 Luye Pharma grants commercialization rights of rivastigmine transdermal patches to Myung In in South Korea
  • 05 Feb 2024 Luye Pharma intends to launch rivastigmine transdermal multi day in South Korea, Japan, Mexico, Thailand and European countries
  • 31 Oct 2023 National Medical Products Administration (NMPA) approves Marketing Authorization Aapplication for rivastigmine twice weekly transdermal patch in Alzheimer's disease
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top